Loading news...
Waters (NYSE: WAT - Get Free Report) and Vicarious Surgical (NYSE: RBOT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Insider and Institutional Ownership 94.0% of Waters shares are
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (OTCID: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery, today announced a series of strategic actions intended to strengthen the Company's financial position, enhance trading liquidity, and support a potential relisting of its common stock on a national exchange. Over the past several months, Vicarious Surgical has implemented significant operational and cost discipline initiatives des.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCID: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results Total operating expenses were $9.3 million in the fourth quarter of 2025, and $15.0 million in the fourth quarter of 2024, a decrease of 38%. Researc.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”). Trading on the Company's Common Stock on the NYS.
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Vicarious Surgical Inc. (the “Company”) — ticker symbol RBOT — from the NYSE. Trading in the Company's Class A common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company's Class A common stock pursuant to Section 802.01B of the NYSE's Listed Compan.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed.
Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company's broader operating model transformation, designed to improve execution, increase development predictabil.
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants (“Warrants”) — ticker symbol RBOT WS — thirty (30) whole warrants are exercisable to purchase one share of Class A common stock of Vicarious Surgical Inc. (the “Company”) from the NYSE. Trading in these Warrants on the NYSE will be suspended immediately. Trading in the Company's Class A common stock — tick.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced its full-year 2026 cash burn guidance. Vicarious Surgical expects full-year 2026 cash burn of approximately $35 million, representing a $10 million improvement from the Company's recently updated 2025 guidance of $45 million. Cash needs beyond existing cash resources to achieve desi.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced an update to full-year 2025 financial guidance. Vicarious Surgical now expects full-year 2025 cash burn of approximately $45 million, representing a $5 million improvement from its previous guidance of $50 million. The improved guidance reflects disciplined cost management initiativ.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that the Company will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference. Vicarious Surgical's management is scheduled to participate in a fireside discussion on Wednesday, December 3, 2025, at 4:30 p.m. Eastern Standard Time. Interes.
Vicarious Surgical Inc. ( RBOT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Stephen From - CEO & Director Sarah Romano - CFO & Treasurer Conference Call Participants Marissa Bych - Gilmartin Group LLC Joshua Jennings - TD Cowen, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon. Thank you for attending the Vicarious Surgical's 2025 Third Quarter Earnings Call.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the third quarter ended September 30, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, November 12, 2025. “Since stepping into this role three months ago, my focus has been on sharpening our execution and.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will now report financial results for the third quarter ended September 30, 2025 after the market closes on Wednesday, November 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase the Company's Class A common stock and pre-funded warrants in a registered direct offering and warrants to purchase its Class A common stock in a concurrent private placement. The combined effe.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the “Board”). Mr. Doherty has served as a member of the Board since June 2025. “Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective,”.
Vicarious Surgical Inc. (NYSE:RBOT ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 AM ET Company Participants Adam David Sachs - Co-Founder, President & Director Sarah Romano - CFO & Treasurer Stephen From - CEO & Director Conference Call Participants Adam Carl Maeder - Piper Sandler & Co., Research Division Eric Evan Anderson - TD Cowen, Research Division Ryan Benjamin Zimmerman - BTIG, LLC, Research Division Marissa Elizabeth Bych - Gilmartin Group LLC Operator Good afternoon. Thank you for attending the Vicarious Surgical's 2025 Second Quarter Earnings Call.
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the second quarter ended June 30, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2025. “Leading Vicarious Surgical from its earliest days through key development milestones has been an extrao.